European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)

You might also be interested in reading Many EU Crypto Entities May Not Know the Correct Deadline for Sustinability Disclosures Under MiCA: Risk Analyst.